Key result
PCR-based next-generation sequencing involves a risk of allelic dropout affecting up to 0.77% of amplicons, reducing diagnostic yield and necessitating validation with Sanger sequencing.
Why the study?
The diagnostic yield of genetic testing for primary cardiomyopathies fails to exceed 60%, and whether allelic dropout reduces diagnostic yield during targeted gene panel sequencing was investigated.
Observational (n=232)
PCR-based next-generation sequencing for primary cardiomyopathies carries a risk of allelic dropout due to variants in primer binding sites, necessitating Sanger sequencing validation.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to possible ADO in negative CMP NGS results; leaves open whether mitigation strategies raise diagnostic yield.
Primary cardiomyopathies (CMPs) are monogenic but multi-allelic disorders with dozens of genes involved in pathogenesis. The implementation of next-generation sequencing (NGS) approaches has resulted in more time- and cost-efficient DNA diagnostics of cardiomyopathies. However, the diagnostic yield of genetic testing for each subtype of CMP fails to exceed 60%. The aim of this study was to demonstrate that allelic dropout (ADO) is a common phenomenon that reduces the diagnostic yield in primary cardiomyopathy genetic testing based on targeted gene panels assayed on the Ion Torrent platform. We performed mutational screening with three custom targeted gene panels based on sets of oligoprimers designed automatically using AmpliSeq Designer® containing 1049 primer pairs for 37 genes with a total length of 153 kb. DNA samples from 232 patients were screened with at least one of these targeted gene panels. We detected six ADO events in both IonTorrent PGM (three cases) and capillary Sanger sequencing (three cases) data, identifying ADO-causing variants in all cases. All ADO events occurred due to common or rare single nucleotide variants (SNVs) in the oligoprimer binding sites and were detected because of the presence of "marker" SNVs in the target DNA fragment. We ultimately identified that PCR-based NGS involves a risk of ADO that necessitates the use of Sanger sequencing to validate NGS results. We assume that oligoprimer design without ADO data affects the amplification efficiency of up to 0.77% of amplicons.
No takes yet. Share an insight, caveat, or question.
Shestak et al. (2021) conducted an observational in Inherited cardiomyopathies (n=232). PCR-based sequencing of targeted gene panels vs. Capillary Sanger sequencing was evaluated on Allelic dropout events. PCR-based next-generation sequencing involves a risk of allelic dropout affecting up to 0.77% of amplicons, reducing diagnostic yield and necessitating validation with Sanger sequencing.
Synapse has enriched 10 related papers. Consider them for comparative context: